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PCARDIOVASCULAR GENOMIC MEDICINE
Genomics and Cardiovascular Drug Development
Andrew S. Plump, MD, PHD,* Pek Yee Lum, PHD†
Rahway, New Jersey; and Seattle, Washington
In the last half century, phenomenal advances have been made in understanding the pathophysiology of cardio-
vascular disease and in developing therapies to reduce cardiovascular risk. Nevertheless, cardiovascular disease
remains the leading cause of death and morbidity in the industrialized world, with rapidly rising prevalence in
developing countries, accounting for 30% of all deaths worldwide. Since the initial availability of statin drugs in
1987, few novel cardiovascular therapies have emerged. Whereas statins reduce the mortality and morbidity
from atherosclerotic heart disease by 30%, the staggering 70% residual cardiovascular risk underscores the
persistent need for novel therapies. Substantial advances in genomic research offer promise to greatly facilitate
cardiovascular drug development. Over the past decade, often termed “the genomics revolution,” such advance-
ments as the emergence of genome-wide genotyping in humans, the industrialization of messenger ribonucleic
acid expression profiling, and the maturation of proteomic and metabolomic methodologies have been made. In
addition, the advancement of informatics to allow the intersection of multiple complex datasets has led to the
field of systems biology. Genomic approaches are already being utilized to drive novel compound pipelines by
helping with the identification and validation of novel targets. In the future, the study of genomics is expected to
support biomarker discovery and development and the identification of responder patient segments. The focus
of the present review is the application of genomics to the development of novel atherosclerosis
therapies. (J Am Coll Cardiol 2009;53:1089–100) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.050c
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pardiovascular disease (CVD) is the most prevalent of all
iseases in both industrialized and developing nations.
espite a reported 60% decrease in the age-adjusted CVD
ortality rate over the past 30 years (1), disease prevalence
emains largely unchanged. According to the American
eart Association, an estimated 80.7 million American
dults (1 in 3) have 1 or more types of CVD (2). Mortality
ata show that CVD was the underlying cause of 36.3% of
ll deaths in 2004, or 1 of every 2.8 deaths in the U.S. (2).
lobally, CVD is the number 1 cause of death; an estimated
7.5 million people died from CVD in 2005, representing
0% of all deaths worldwide (3). These grave statistics are
rrespective of recent advances in understanding the patho-
hysiology of CVD, strong educational efforts promoting
ealthy life-style changes, and the development of highly
ffective therapies for treating the underlying risk factors
nd sequelae of acute ischemic events.
The process of drug development has become increas-
ngly difficult, despite various methodologic improvements
4), and since the introduction of statins in 1987, few novel
VD therapies have emerged. Of the 16 major cardiovas-
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nd †Rosetta Inpharmatics, LLC, a wholly owned subsidiary of Merck & Co., Inc.,
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008, accepted November 24, 2008.ular (CV) drug classes, only 4 (angiotensin receptor block-
rs, brain natriuretic peptide mimetics, glycoprotein IIb/IIIa
nhibitors, and direct rennin inhibitors) have become avail-
ble in the post-statin era (Table 1) (5,6). The development
f a novel CV therapy takes 15 years and, including the
arge number of failures, costs $800 million (7). There is
high attrition rate in pre-clinical and early clinical drug
evelopment, reflecting a need for risk-based decision mak-
ng. During the development of a successful therapy, many
nterventional targets and chemical compounds are gradu-
lly reduced to fewer candidates that are ultimately tested in
linical studies. As the number of targets and compounds
ecreases geometrically throughout the stages of drug de-
elopment, the cost increases exponentially; hence, decisions
ade further along the development continuum have incre-
entally higher stakes.
Challenges to CV drug development include a scarcity of
ccepted surrogates for CV outcomes and a lack of useful
latforms to assess direct vascular effects of promising new
rug candidates (8). The most prominent gaps are the lack
f 1) valid drug targets and pre-clinical models that predict
fficacy and safety in humans; 2) biomarkers that predict CV
linical outcomes such as myocardial infarction (MI) and
nstable angina; 3) responder patient segments that can
ncrease the efficiency and probability of success of outcome
rials; and 4) drug/diagnostic combinations. Genomic ap-
roaches are currently being applied in industry, biotech-
ology, and academic settings to address many of these gaps
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Genomics and Cardiovascular Drug Development March 31, 2009:1089–100(Table 2) (9–19). The present
review focuses on the scientific
challenges facing CV drug devel-
opment and the application of
genomics to the development of
novel CVD therapies through
identification and validation of
drug targets, biomarker discov-
ery, and outcome trial design.
Identification and
Validation of Drug Targets
A functional definition of a drug
target is any molecular target
which, when modified by a ther-
apeutic agent, may result in a
pharmacologic change associated
with a clinical benefit. Given the
large number of potential targets
and the mounting costs as drug
development progresses from
early to later stages, the decisions
made during basic discovery are
of paramount importance. Tar-
get validation refers to the point
at which sufficient scientific evi-
dence exists to support that ther-
apeutic modification of the target
may result in clinical benefit. In
the pre-genomic era, validation
would often involve a pharmaco-
ogic agent that could modulate a target in a pre-clinical
isease model. The agent would typically be identified from
creening large libraries of chemical compounds, and sub-
equent medicinal chemistry techniques would be used to
efine the molecular structure to “dial in” certain character-
stics, such as specificity and potency. Once refined, the
olecule would be used to study efficacy in cell-based and
ater pre-clinical models to establish a target as valid. This
pproach is time consuming and not particularly scaleable.
In the genomics era, the number of potential drug targets
as increased dramatically. Although pharmacologic target
alidation is still a useful precursor in drug development,
ew tools have emerged to identify, validate, and prioritize
reater numbers of plausible drug targets in basic discovery.
he greatest impact of genomics on drug development has
een in the area of target identification and validation.
ere, the past and present contributions of mouse and
uman genomics and the promise of systems biology to
arget identification and validation are considered. When
nterpreting genomic datasets, one must consider the con-
ept of causation versus association. Figure 1 provides a
implified overview of where and when a genomic marker is
ausal or reactive. The ability to assign causality is critical to
Abbreviations
and Acronyms
apo  apolipoprotein
CAD  coronary artery
disease
CHF  congestive heart
failure
CRP  C-reactive protein
CV  cardiovascular
CVD  cardiovascular
disease
DM  diabetes mellitus
DNA  deoxyribonucleic
acid
FH  familial
hypercholesterolemia
GWAS  genome-wide
association study
HDL  high-density
lipoprotein
HDL-C  high-density
lipoprotein cholesterol
LDL  low-density
lipoprotein
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
RNA  ribonucleic acid
SNP  single nucleotide
polymorphismarget identification. tenomic applications to drug target identification and
alidation. MOUSE GENETICS. The mouse has emerged as the
referred species for the application of genomics to target
dentification and validation (20,21). Various genomic meth-
ds have been applied to the mouse for the identification and
alidation of atherosclerosis drug targets, ranging from candi-
ate gene approaches, such as transgenic and gene knockout, to
pen system approaches, such as gene expression profiling,
roteomics, and genetics. One major drawback to using rodent
odels to study atherosclerosis is that rats and mice have a
ifferent lipoprotein profile than humans and carry most of
heir plasma cholesterol in the high-density lipoprotein (HDL)
raction. Rodents that have not had genetic manipulation of
ey lipoprotein-determining genes, such as apolipoprotein
apo) E or the low-density lipoprotein (LDL) receptor, do not
evelop atherosclerosis.
Genetic manipulation has been used to generate mouse
odels of atherosclerosis. Mice deficient in apoE or the
DL receptor develop a human-like atherosclerosis that has
een extensively characterized (22–24). Lesions in apoE-
eficient mice initiate as fatty streaks and progress to
dvanced fibroproliferative plaques, containing inflamma-
ory infiltrate, cholesterol deposits, and necrotic cores
25,26). Although studies have demonstrated that these
esions can rupture and lead to atherothrombosis (27–29),
he mouse is not prone to plaque vulnerability. This lack of
ulnerability poses a massive problem for the field. While
ouse plaque rupture models have been described, the
eproducibility and validity of these models remain in
uestion. The lack of plaque rupture models has severely
imited the ability to use the mouse as a model for
therosclerosis. Nevertheless, these mouse models have been
nstrumental in providing a high throughput system for
ssessing the effects of genetic manipulation and therapeutic
nterventions on atherosclerosis plaque burden. Given the
ompositional similarities of plaque in atherosclerosis-prone
ice as compared to humans, there is still value in the
odel. Many studies have been published demonstrating
he potential atherogenicity of candidate genes and the
theroprotective potential of therapeutics (30). The trans-
ation of these effects to humans has not been realized, given
he long time delay in establishing human outcomes.
Of particular interest is the ability of the mouse model to
lucidate the proatherogenic role of inflammation and the
ntiatherogenic role of high-density lipoprotein cholesterol
HDL-C). The strong causal relationships established in
he mouse model underscore the therapeutic potential of
nti-inflammatory and HDL-C–raising therapies. Al-
hough progress in the development of anti-inflammatory
gents has been limited by the lack of necessary clinical tools
or establishing proof of concept, advancements in HDL-
–based therapies have been made, and several outcomes
rials are currently ongoing or planned (31,32).
Studies in apoE-deficient mice have provided compelling
vidence to suggest a causal association between inflamma-
ion, characterized by macrophage infiltration and activity in
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March 31, 2009:1089–100 Genomics and Cardiovascular Drug Developmentlaque, and atherosclerosis (21). Mice with naturally-
ccurring mutations in granulocyte macrophage–colony
timulating factor that fail to develop differentiated tissue
acrophages have markedly reduced atherosclerosis (33).
hese data were substantiated in a recently constructed
ouse atherosclerosis model, the apoE3-Leiden mouse
34). Elevated plasma lipids and atherosclerosis developed
nly when this transgenic animal was fed a high-fat/high-
holesterol diet. When switched to a low-fat chow diet, the
ipid profile normalized, and atherosclerosis development
eased and eventually regressed. Before the regression of
therosclerosis, macrophages completely disappeared from
he plaque, suggesting a causal relationship between mac-
ophage presence and plaque development. The role of
nflammation in atherosclerosis has been further substanti-
ted by other studies evaluating perturbations of macro-
hage differentiation and function through genetic and
herapeutic intervention. One noteworthy example is the
isruption of the chemokine monocyte chemoattractant
rotein-1 or its receptor CCR2 and the use of anti-CCR2
herapeutics, which significantly diminish atherosclerosis
14,15).
The mouse model has also been instrumental in under-
tanding the relationship between atherosclerosis and HDL
iology. Human epidemiologic studies have implicated
Major CV Disease Therapeutic Classes
Table 1 Major CV Disease Therapeutic Clas
Therapeutic Class CV Therap
Angiotensin-converting enzyme inhibitors Hypertens
Alpha-blockers Hypertens
Angiotensin receptor blockers Hypertens
Antiarrhythmics Arrhythmi
Antithrombotics (anticlotting agents) Atheroscle
Beta-blockers Hypertens
BNP mimetics CHF
Calcium-channel blockers Hypertens
Cholesterol, niacin
Cholesterol, statins Atheroscle
Cholesterol, absorption inhibitors Atheroscle
Diuretics Hypertens
Glycoprotein IIb/IIIa inhibitors Atheroscle
Inotropic agents CHF
Renin inhibitors HTN, CHF
Vasodilators Hypertens
Some older drugs are not found in the Food and Drug Administration rec
In these cases, the dates are approximated from available literature. *F
for cardiac arrhythmia from 1918 (6). ‡Lauder Brunton, father of mod
BNP  brain natriuretic peptide; CHF  congestive heart failure; HTDL as atheroprotective (35); however, the atheroprotec- iive benefits of high HDL are often confounded by concur-
ent low triglyceride levels (36). In addition, genetic defi-
iencies in HDL that are not associated with changes in
riglycerides do not always associate with atherosclerosis
37), and genetic causes of HDL elevation do not always
orrelate with atheroprotection (38). Moreover, several drug
ntervention studies in humans (39–41) have failed to
emonstrate that pharmacologic elevation of HDL results
n atheroprotection. The HDL-raising drug niacin has been
ssociated with CV benefit, but it also lowers triglycerides,
DL-C, and lipoprotein(a) (42), leaving uncertainty as to
he exact mechanism by which niacin confers atheroprotec-
ion. The mouse models, however, provide definitive evi-
ence that the primary HDL apolipoprotein, apoA1, is
theroprotective. Transgenic overexpression, adenoviral-
ediated delivery, and intravenous infusion of apoAI in an
therosclerosis mouse model produced dramatic and consis-
ent reductions in atherosclerosis (30). These findings pro-
ide support for the continued pursuit of therapies that raise
DL through increasing apoA1 production.
Despite the major advances that the apoE-deficient and
ther mouse models have made to the study of atheroscle-
osis, the ultimate value of the mouse to the development of
ovel atherosclerosis therapies has not been defined. Unbi-
sed classical forward mouse genetics may offer additional
arget Year First Used for Indication
F 1981 captopril*
1987 terazosin*
1976 prazosin*
F 1995 losartan*
1948 lidocaine*
1950s diphenylhydantoin*
1950s quinidine†
1967 propranolol*
1939 heparin*
1965 aspirin*
1940s dicumarol*
1954 warfarin*
F 1967 propranolol*
2001 nesiritide,* a recombinant human BNP
gina 1981 verapamil*
1981 nifedipine*
1955 niacin*
1987 lovastatin*
2002 ezetimibe*
F 1958 chlorothiazide*
1959 hydrochlorothiazide*
2003 abciximab*
1974 dopamine*
2007 aliskerin*
1981 nitroglycerin‡
r first approval or for a new indication for cardiovascular (CV) diseases.
d Drug Administration records; also see Zycher et al. (5). †Recognized
armacology, used nitroglycerin to relieve angina in 1867.
pertension.ses
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b
b
b
i
t
s
F
s
i
l
c
n
b
t
r
c
n
a
q
f
H
p
a
g
d
b
K
a
Study; LDL  low-density lipoprotein; LDL-C  low-density lipoprotein cholesterol; MCP  monocyte ch
Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22; SNP  single nucleotide poly
1092 Plump and Lum JACC Vol. 53, No. 13, 2009
Genomics and Cardiovascular Drug Development March 31, 2009:1089–100y means of dietary manipulation, establishment of recom-
inant inbred strains, or construction of F2 intercrosses
etween strains of mice with varying susceptibility. For
nstance, the C3H mouse strain is highly resistant, whereas
he C57BL/6 is partially sensitive to diet-induced athero-
clerosis; these 2 strains have been used as parental strains in
2 intercrosses to study the genetic determinants of athero-
clerosis. Through quantitative trait locus mapping of var-
ous F2 mouse crosses, several atherosclerosis susceptibility
oci have been identified (43–46). These early genetic
rosses highlight the potential to use unbiased whole ge-
ome approaches to identify novel atherosclerosis suscepti-
ility loci. However, identifying the true causal gene from
he susceptibility loci has been challenging, because loga-
ithm of the odds (LOD) peaks defined by these inter-
rosses are typically broad, with multiple genes lying be-
eath the peak. Thus, the use of unidimensional genetic
pproaches to extrapolate from quantitative trait locus to
uantitative trait gene has proved time consuming and often
utile.
UMAN GENETICS. Human genetics offers tremendous op-
ortunities for target identification and validation. The
bility to identify causal genes for diseases with Mendelian
enetic inheritance patterns has led to significant gains in
rug development. More than 30 years ago, the association
sis Therapy
Traditional Example Genomic Example
delian genetics to identify LDL receptor
y as the cause of FH and mechanistic
o show that HMG CoA reductase
down-regulates LDL receptor levels
evelopment of statins
Genome-wide association studies and
expression SNP identify a genetic
variant locus on chromosome
1p13 that implicates several
genes (SORT1, CELSR2, PSRC1) as
a target for LDL-C and CV outcome
reductions (9,10)
Resequencing (11–13): Resequencing
of humans with low LDL-C
identifies rare PCSK9 loss of
function alleles linked to very low
LDL-C (13), and identifies PCSK9
as therapeutic target for
hypercholesterolemia
poE-deficient mice show the
ne MCP1 and its receptor CCR2 are
nic, supporting both as
rosclerosis targets (14,15)
Systems biology approach in a mouse
F2 cross identifies hydroxysteroid
(11-beta) dehydrogenase 1
(Hsd11b1) as causal for metabolic
syndrome traits (16)
LDL-C establish POC for statins No good example to date
tion of CV outcome benefit from
tin was shown in the HPS trial (17)
Retrospective identification of
association between Kif6 and CV
outcome benefit from statin in
PROVE IT–TIMI 22, CARE, and
WOSCOPS trials (18,19)
percholesterolemia; HMG CoA 3-hydroxy-3-methylglutaryl co-enzyme A; HPS Heart Protection
emoattractant protein; POC  proof of concept; PROVE IT–TIMI 22  Pravastatin or Atorvastin
morphism; WOSCOPS  West of Scotland Coronary Prevention Study.ey Decision Phases in the Development of an Atherosclerosis Therapy
Table 2 Key Decision Phases in the Development of an Atherosclero
Phase Application
Pre-clinical target identification Identify novel targets for CV disease
therapies that have a high
probability of providing outcome
benefit
Use of Men
deficienc
studies t
inhibition
lead to d
Pre-clinical target validation Demonstrate that a novel therapy
has efficacy in an established
pre-clinical model
Studies in a
chemoki
atheroge
antiathe
Phase 2: proof of concept Establish POC in patients in phase 2
study that a therapy will have
outcome benefit; biomarkers
often used to establish POC in
phase 2
Changes in
Phase 3: establish efficacy
and safety
Demonstrate CV outcome benefits Demonstra
simvasta
poE apolipoprotein E; CARE Cholesterol and Recurrent Events; CV cardiovascular; FH familial hyFigure 1 Causation Versus Association
To identify a new drug target, one must differentiate between a causal observa-
tion and one that is reactive or merely associated with a biochemical change
and/or phenotype of interest. (A) A classic example of a causal sequence is
demonstrated by the top row. A polymorphism in deoxyribonucleic acid (DNA)
leads to a change in ribonucleic acid (RNA) that causes a change in protein
activity or levels that causes a change in clinical phenotype. For example, non-
sense mutations in the PCSK9 gene lead to reduced PCSK9 RNA and protein
levels, decreased low-density lipoprotein cholesterol, and less coronary artery
disease. (B) Changes in RNA and protein can be causal or reactive to a clinical
phenotype. Here, a DNA polymorphism leads to a downstream change in RNA1
and protein1 that causes a clinical phenotype. The clinical phenotype then
leads to reactive changes in RNA2 and/or protein2. The elevation in C-reactive
protein seen in patients with coronary artery disease is an example of a reac-
tive protein change.etween familial hypercholesterolemia (FH) and the LDL
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March 31, 2009:1089–100 Genomics and Cardiovascular Drug Developmenteceptor was identified through the study of fibroblasts
erived from FH patients (47,48). The research demon-
trated that fibroblasts deficient in LDL receptors had
ignificantly up-regulated 3-hydroxy-3-methylglutaryl co-
nzyme A (HMG CoA) reductase, the rate-limiting en-
yme in cholesterol biosynthesis (48). The high risk of
oronary artery disease (CAD) in patients with FH, to-
ether with the growing body of epidemiologic data asso-
iating LDL-C with CAD, validated HMG CoA reductase
s an antiatherosclerosis drug target. This led to the devel-
pment of statin drugs, which are responsible for reducing
he morbidity and mortality from CAD by 30% (49).
Recent successful family-based studies, such as the dis-
overy of associations between genetic variation in LRP6
ith metabolic syndrome and CAD and between PCSK9 or
RH and LDL and CAD, continue to highlight the power
f Mendelian genetics for drug target identification and
alidation (13,50,51). Despite the potential of Mendelian
enetic approaches, such cohorts are rare and small in size
47,48,50,52), offering valuable but limited information.
opulation-based human genetic approaches offer a signif-
cantly greater opportunity than do Mendelian genetics, but
ntil recently, have been technically challenging. Efforts
ver the past 10 years have focused on biased, population-
ased genetic approaches, in which candidate genetic vari-
nts from 1 to several genes were evaluated for association
ith human disease. These approaches have offered little to
rug discovery, as the veracity of associations in almost all
ases has been unclear because of lack of reproducibility.
The recent completion of the human genome sequence
nd the HapMap, in addition to substantial reductions in
he cost of genotyping and sequencing, have made genome-
ide association studies (GWAS) a reality (53). Several
WAS for metabolic and CV diseases have been recently
ublished (9,10,54). Although data from these studies
equire further evaluation and the ultimate value of GWAS
emains unknown, several loci have been associated with
DL, HDL, and CAD. While these associations are
ncouraging, the physical proximity of a single nucleotide
olymorphism (SNP) and gene is only a starting point for
onsidering causality. In drug development, strong evidence
or association of the SNP with disease, the identification of
he causal gene, and a high probability that a therapeutic
gent can be developed to agonize or antagonize a given
arget (i.e., “druggability”) are necessary to establish a valid
rug target. In addition, for a target to be “druggable,” its
unction must be well understood, as is common with
ertain enzymes or cell surface receptors.
A recent association was made for a locus on chromosome
p13 with LDL-C and CAD (9,10,54). The 1p13 SNP lies
n close proximity to 3 genes: cadherin-EGF-LAG 7-pass
-type receptor 2 (CELSR2), proline/serine-rich coiled-
oil 1 (PSRC1), and sortilin 1 (SORT1). The transforma-
ion of a genetic association to causality requires the
unctional consequence of an SNP that associates with
isease. Since most genetic variation occurs in intragenic or toncoding sequences, recent attention has been on “func-
ionating” SNPs by their association with gene expression.
ne mechanism for ascribing function to an SNP is by
stablishing its association to gene expression. This is
ermed an expression SNP (55–60). Functional SNPs (i.e.,
hose that change gene expression levels) can be identified
y assessing variations in whole genome gene expression by
icroarray analyses in a given tissue across many people and
hen associating expression with genetic variation (61).
nterestingly, the SNP at 1p13 that associates with LDL
nd CAD also has a highly significant association with
xpression levels of the 3 proximal genes, CELSR2,
SRC1, and SORT1 (9,54,61), strongly implicating this
NP as the causal genetic variation and 1 or all of these
enes as causal for CAD. This breakthrough analysis has
ow reduced the potential underlying gene(s) from many in
hat region to 3. This narrowing of the likely candidates
ow allows more focused analyses using knockdown and
nockout technologies in vitro and in vivo, which will
nable further in-depth investigations around these 3 genes
nd the pathway they impact, resulting in resolution of the
egion and perhaps a druggable novel target.
The potential of GWAS was demonstrated by the recent
ssociation of multiple SNPs located in a gene-poor region
n chromosome 9p21 with type 2 diabetes mellitus (DM)
nd the risk of MI (54,62,63). These SNPs, although all
ocated very close to each other in the same region, have
ndependent associations to DM and the risk of MI (64).
he association of the 9p21 region to MI has been repli-
ated in several studies, all showing an association indepen-
ent from known risk factors. This finding could lead to the
dentification of novel nonlipid antiatherosclerosis drug
argets. Although the 9p21 SNP is close to several genes
cyclin-dependent kinase inhibitor 2B, cyclin-dependent
inase inhibitor 2A, and methylthioadenosine phosphory-
ase), none has an obvious connection to CAD nor has any
een implicated as causal for the association. Two recent
tudies suggest that a noncoding ribonucleic acid (RNA),
ntisense noncoding RNA in the INK4 locus (ANRIL),
ay be the causal gene underlying the association (64,65),
ut these data do not provide conclusive evidence of an
ssociation. If ANRIL should prove to be the causal gene,
dditional data will be needed to elucidate how a noncoding
NA transcript is driving risk. Moreover, because ANRIL
s not “druggable,” potential drug targets would need to be
dentified through an understanding of the ANRIL genetic
etwork. Human genetics offers extremely powerful tools
or identifying disease causal regions of the genome, but
ransforming genetic association into disease causality will
equire significant effort and, in many cases, turning these
ssociations into druggable targets will require more sophis-
icated systems biology approaches. If a druggable gene is
dentified in this region through additional analyses, then
he therapeutic potential of this region is high. The SNPs in
his region could be tested and used as markers to segment
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Genomics and Cardiovascular Drug Development March 31, 2009:1089–100population according to their risk of MI or type 2 DM,
nd those patients can be more aggressively treated.
YSTEMS BIOLOGY. Genetics offers a unique opportunity to
ssociate heritable variation with disease; however, the
hallenges in defining causality (Fig. 1) and the potential
hat the causal genes are not druggable underscores the need
or better genome-mining strategies. One approach that is
aining momentum is systems biology, the science of
stablishing multiple genomic datasets which, when inter-
ected and queried using sophisticated informatics and
tatistical modeling tools, can establish causal associations of
ene pathways with disease. Systems biology uses not just
enetics, but also such datasets as those from multiplexed
mmunoassay phenotyping, RNA profiling, proteomics, and
etabolomics.
A proof-of-principle experiment for a systems biology
pproach for target identification demonstrated the power
f coupling gene expression with genetics (16,55,61,66,67).
n an F2 mouse cross with multiple metabolic pheno-
ypes, hydroxysteroid (11-beta) dehydrogenase 1
Hsd11b1), zinc finger protein 90 (Zfp90), and other
enes were found to be causal for metabolic traits.
econstructed gene networks were used to assign func-
ion and position the genes of interest to a specific
iological pathway, thereby strengthening the argument
f causality for a phenotype (68 –70). Causal genes of
nterest were later tested in either knockout or transgenic
ice, or by pharmacologic intervention, confirming the
ypotheses established by causality and network analysis.
ypotheses generated from this approach allowed test-
ble studies. For example, when mice overexpressing the
ene Zfp90 were analyzed, they had significantly higher
at mass than the controls, as predicted by the systems
pproach (16). Thus, the use of causality and networks
as allowed for the identification of key genes likely to
rive disease, separating them from merely reactive ones.
Another recent application of systems biology has
trongly implicated oxidative phosphorylation and mito-
hondrial dysfunction in the pathogenesis of atherosclerosis.
n an F2 mouse cross from C57BL/6 and C3H parental
trains in an apoE-deficient background, in which athero-
clerotic lesions were among the phenotypes scored, gene
xpression profiling showed that gene expression variation
n liver and gonadal fat pads had a major role in atheroscle-
osis (71). Many gene expression quantitative trait loci in
iver and adipose were linked both in trans and cis to
therosclerotic lesions. The association of pathways to
therosclerosis provides a powerful tool for the identifica-
ion of novel targets. In contrast to this integrative systems
pproach, the classical approach utilizing genetics alone
dentifies only loci, not genes or pathways.
Network analysis is another approach that is gaining
ttention. Networks are informatics-driven reconstructions
f complex interactions (68,72–74). Many network analyses
or cardiovascular diseases have been restricted to networks (erived solely from the literature or whole genome gene
xpression profiling (75–77); these approaches can provide
seful information about how a pathway might be regulated
n a given disease state, but do not discern causality, which
s critical to the identification of a drug target. Information-
ich networks are being developed to overcome the limita-
ions of literature-only or gene-expression–only networks.
n particular, Bayesian and gene–gene correlation networks
econstructed from F2 mouse crosses using both genetic and
ene expression data have been useful in providing context
o a gene of interest and assessing whether it is causal and,
hus, a disease drug target (16,66,68,69,78). One study
howed that a macrophage-enriched network derived from
n F2 mouse cross contained many genes with causal
elationships to metabolic phenotypes such as body weight
66); however, additional data from closed systems were
eeded to elevate these genes from candidate to validated
argets. The 3 genes in this network, lipoprotein lipase,
actamase beta, and protein phosphatase 1-like, were vali-
ated as obesity genes, through either targeted gene knock-
own or transgenic approaches, strengthening the associa-
ion between this network and metabolic disease traits.
The systems biology and network approaches have been
teadily gaining ground for use in mice; however, progress in
uman samples has been slow, likely due to the lack of
uman samples available for expression profiling. Neverthe-
ess, recent studies have demonstrated the potential power
f using gene expression to identify transcripts that are
ssociated with SNPs in humans. For instance, expression
rofiles from blood or tissues (e.g., liver) have been used to
dentify expression SNPs. In addition, studies are under way
o combine networks derived from both mouse F2 crosses
nd humans with liver-derived expression SNPs to identify
isease genes (61).
A systems biology approach has also been informative in
xcluding a potential candidate drug target, C-reactive
rotein (CRP), which is a biomarker of inflammation and
as a strong association with CAD (79). There has been
ubstantial debate as to whether CRP associates with CAD
s a disease marker or as a causal factor. If the latter, CRP
ould be a good drug target. Genetic variation in the CRP
ocus has effects on circulating CRP levels. Systems biology
pproaches have been used, leveraging epidemiologic asso-
iations of CRP and metabolic syndrome phenotypes to-
ether with Mendelian randomization modeling to exclude
ausality (80–82). In these Mendelian randomization stud-
es, patients are, in a sense, randomly allocated to high
ersus low CRP arms based on CRP genetic variation
nown to affect CRP expression. The genetic anchoring
rovides a basis for segmenting causal (genetic) versus
eactive secondary (e.g., inflammatory) causes of CRP level.
ecause of a less than expected difference in the prevalence
f clinical phenotype between the high and low CRP
enotype patients, the studies concluded that CRP is not causal
the concept of Mendelian randomization is schematized in
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RP as a marker of disease, but not a causal factor.
Systems biology will help us to understand complex
isease. The identification of SNPs or loci associated with
isease is an important first step. The functionation of that
NP is a critical next step and, in many cases, will require a
ystems biology approach (Fig. 3). Networks will allow us to
educe the information-rich, high-density data that emerge
rom systems biology into bite-size pieces that are relevant
nd can be properly processed. Networks and pathways can
Figure 2 Mendelian Randomization
Expected outcome from a hypothetical randomized clinical trial (RCT) of selective C
sis, if CRP were causal in the development of cardiovascular (CV) events and effec
of CRP gene associated with low and high CRP, respectively. For simplicity, only ho
Humphries (83).
Figure 3 Systems Biology
A systems approach to refine the list of putative disease causal genes for a genom
tionated” by using orthogonal datasets, such as gene expression, networks, and e
from various F2 mouse intercrosses and human genetics studies, microarray expelso provide a priori knowledge about a disease, allowing a
re-selected set of SNPs to be tested in a given cohort,
hereby reducing the likelihood of false discovery due to
ultiplicity. Such innovative genomic approaches will be
ecessary to maximize the value of GWAS.
iomarkers and Proof of Concept
major challenge in developing novel CV therapies is the
bility to assess clinical efficacy or proof of concept in a
ive protein (CRP)–lowering intervention, and from Mendelian randomization analy-
reversible (perhaps by high-risk phenotype). The “aa” and “AA” refer to alleles
ous persons are shown. Reprinted with permission from Hingorani and
e association study locus. Single nucleotide polymorphisms (SNPs) are “func-
sion SNPs. These orthogonal datasets can be derived from networks derived
s, and other genome-wide or pathway-focused cell-based screens.-react
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Genomics and Cardiovascular Drug Development March 31, 2009:1089–100mall, short-duration phase II clinical trial. The ultimate
oal of most CV therapeutics is to reduce the risk of future
linical events, such as MI or stroke. Because the assessment
f CV event reduction requires expensive, long-term out-
ome trials, a high probability of success is necessary for a
linical research organization to perform the study and for
nvestigators and patients to consent to the years of clinical
esting. Despite assurances, recent CV clinical outcome
rials have shown no benefit or even harm, including the
RISE (Aggressive Reduction of Inflammation Stops
vents) trial for the direct vessel wall acting therapy,
GI-1067 (succinobucal) (84), and the ILLUMINATE
Investigation of Lipid Level Management to Understand
ts Impact in Atherosclerotic Evens) trial for the HDL-C–
aising cholesteryl ester transfer protein inhibitor, torce-
rapib (41). These failures underscore the need for biomark-
rs that can predict outcomes, reducing the risks associated
ith testing novel CV therapies.
Genomic approaches are currently under way to develop
ovel, predictive biomarkers, particularly for plaque vulner-
bility and HDL function. Plaque vulnerability is an area in
hich genomics may facilitate proof-of-concept decisions.
iven the absence of predictive plaque vulnerability biomark-
rs, the decision to perform a clinical outcome study on the
fficacy of AGI-1067 in reducing plaque vulnerability was
ade based on data from intravascular ultrasonography studies.
ecause intravascular ultrasound measures plaque burden, not
ulnerability, it may not have been the appropriate tool for
ssessing the beneficial effects of an agent designed to stabilize
Figure 4 BioIMAGE Study Design
BioIMAGE is a payor-based observational study to identify imaging and/or circulati
ment over traditional risk assessment (Framingham risk scoring). The study will en
from Chicago, South Florida, and Kentucky without known CV disease or other ser
serve as nonimaging controls. Physical measurements include electrocardiogram a
and abdominal aorta computed tomography (CT) coronary artery calcium scoring in
(MRI), aorta CT, and carotid/aorta FDG-positron emission tomography/CT in a sub
cleic acid (DNA) will be collected for genomic and candidate biomarker studies in a
(2Q) of 2009 and longitudinal follow-up in 2012. 1Q  first quarter.laque. A variety of genomic markers are being considered as
redictors of CV events. For instance, gene expression of
irculating white blood cells has led to the identification of
NA markers of CAD (85,86). Additionally, correlations
etween gene expression in mouse atherosclerotic plaque and
uman coronary disease have been studied (87). These markers
ill require validation, ideally by longitudinal association with
utcome, and then be used to help establish proof of concept
or novel therapeutics.
High-density lipoprotein is a highly predictive CAD risk
arker; however, the biology of HDL appears to be more
omplex than that of LDL, and HDL function may be
ore important than HDL level in driving CAD risk.
roteomic approaches are being used to understand the
omposition of HDL and identify markers that render
DL atheroprotective. Using proteomics, proteins have
een identified on HDL in differential amounts in patients
ith CAD versus healthy controls, and a subset of these
roteins change after statin therapy (88). These observations
uggest that the HDL proteome may be useful in identify-
ng novel HDL-raising compounds for proof of concept and
ovement into clinical outcome studies.
The High Risk Plaque (HRP) initiative is a private-
ublic partnership that was recently formed to advance the
nderstanding, recognition, and management of coronary
vents (89). The HRP initiative has implemented an im-
ortant research study known as BioIMAGE, a biomarker
alidation and discovery study initiated in 2008 to identify
ovel risk markers for heart attack and stroke (Fig. 4). The
markers that predict 3-year cardiovascular (CV) events with incremental improve-
300 Humana members ages 55 to 80 years (male) or 60 to 80 years (female)
edical conditions, of whom 6,000 will undergo imaging studies and 1,300 will
kle-brachial index; imaging measurements include carotid artery ultrasonography
000 imaging enrolled subjects and carotid artery magnetic resonance imaging
the 6,000 imaging participants. Plasma, ribonucleic acid (RNA), and deoxyribonu-
icipants. The study is expected to complete enrollment in the second quarterng bio
roll 7,
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nd an
all 6,
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008 and has a target completion date in the first quarter of
009 (90). Patients undergo an extensive set of baseline
iomarker analyses (imaging and circulating) and are mon-
tored longitudinally to track clinical events. This multimo-
ality, information-rich study will provide valuable data on
n extensive set of imaging, proteomic, metabolomic, gene
xpression, and genetic markers that should facilitate proof-
f-concept decision making for future CV therapies and
ovel diagnostics to assess patient risk and therapy response.
utcome Trials and Responder Populations
Personalized medicine” refers to the use of information and
ata from a patient’s phenotype, genotype, or level of gene
xpression to stratify disease, select a medication, provide a
herapy, or initiate a preventative measure that is specifically
uited to that patient at the time of administration. With
pproval rates for novel therapies dropping precipitously and
he challenges and costs associated with developing novel
V therapies rising steeply, the hope of developing a
ersonalized approach to medicine is a distant reality. A
ore realistic goal is that of “segmentalized medicine” and,
o a certain extent, reflects the current state, in which
egments are defined by clinical or biochemical phenotypes.
n obvious example is the segmentation of patients with
levated LDL-C or known CAD for treatment with statins.
hypothetical promise of genomics is the ability to identify
esponder segments based on a molecular, as opposed to
henotypic, understanding of disease.
A potential application of the segmentalized medicine
pproach is the identification of patients at elevated risk for
n adverse effect or who would be more likely to derive
enefit from a given therapy. Recent experience with war-
arin represents an example in which markers have identi-
ed patients at risk for adverse effects. Polymorphisms in a
arfarin-metabolizing enzyme, CYP2C9, and its target,
itamin K epoxide reductase complex 1 (VKORC1), signif-
cantly affect the warfarin therapeutic window (91); these
ata have become incorporated into the warfarin product
abel (92). However, the use of genotype to guide warfarin
osing has not become standard of care because pharmaco-
enetic determinants of warfarin action account for only
50% of its variability. Moreover, prospective clinical
tudies to demonstrate outcome and safety benefit with
harmacogenetic-based prescribing are lacking.
A more recent example of a pharmacogenomic safety
iomarker has been the discovery of an association between
ommon variants in solute carrier organic anion transporter
amily, member 1B1 (SLCO1B1) and statin-induced my-
pathy (93). SLCO1B1 encodes organic anion transporting
olypeptide 1B1, a transporter, for the hepatic uptake of
tatins. Several studies have demonstrated that genetic varia-
ion in this transporter leads to increased circulating statin (94).
ore stringent guidelines are emerging for LDL-C targets,
articularly in high-risk patient populations, driving the pre- ecription of higher statin doses, which are associated with an
ncreased incidence of myopathy. The SLCO1B1 high-risk
lleles could be used to identify patients at risk for myopathy
ith high-dose statins, for whom LDL-C–lowering ap-
roaches beyond statins might be preferred.
Methodologically, there are 2 approaches to identify
atient segments: retrospective and prospective. In the
etrospective approach, a clinical trial is conducted in a
road population and then markers, whether genetic,
enomic, or other, are studied to identify in a hypothesis-
enerating manner a responder population (i.e., patients
ith the greatest therapeutic index of efficacy over safety).
utative markers are subsequently validated in a prospective,
ypothesis-testing clinical trial. This approach was used for
he warfarin CYP2C09 and VKORC1 associations; obser-
ations were first made in retrospective studies and then,
ince the genetic variants are frequent and the prothrombin
ime end point continuous, prospective studies were per-
ormed to validate the biomarkers. For the SLCO1B1
ariants, the data demonstrating an association to myopathy
ere retrospective. Although the variants are frequent, the
yopathy event is not, occurring in 0.2% of patients on
ower statin (95), making prospective confirmation difficult.
urther, given the strength of the association and the
echanistic rationale, it would not be ethical to study this
ssociation prospectively.
While the prospective approach appears straightforward,
n areas outside of oncology, it has not proven successful. In
VDs, for which it is increasingly necessary to demonstrate
utcome benefit to warrant the use of novel mechanisms,
his approach is time consuming and costly as it involves
oing from a hypothesis-generating trial to a hypothesis-
esting trial in which the outcome is CV events. Neverthe-
ess, the retrospective approach has resulted in interesting
ypotheses that require prospective validation. In a statin
utcome trial, PROVE IT–TIMI 22 (Pravastatin or Atorv-
stin Evaluation and Infection Therapy–Thrombolysis In
yocardial Infarction 22), a variation in a kinesin micro-
ubule transport gene, KIF6, was identified as a putative
arker for statin response. Carriers of a common (50%
arrier frequency) KIF6 719Arg allele were found to have an
30% increased risk of CAD and a significantly greater
esponse to statin treatment versus noncarriers (18,19,96).
he identification of the KIF6 719Arg allele was made
hrough a candidate gene rather than a genome-wide
pproach (96), leaving speculation as to whether an unbi-
sed GWAS would yield more and better predictive mark-
rs. Although statins produce considerable reductions in CV
isk, the residual risk of CAD has been estimated as high as
0% (49). Could the KIF6 “nonresponder” or a yet to be
iscovered variant define a responder segment for other
onstatin therapies?
The prospective approach may be a more practical one.
ere, genomics are applied to dissect disease pathways to
dentify not only targets but also biomarkers. The biomark-
rs can then be used to prospectively identify responder
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Genomics and Cardiovascular Drug Development March 31, 2009:1089–100egments and response to therapy. A risk associated with
his approach is mismatching of the segment with the drug,
ut this possibility must be considered against the alterna-
ive risk of failing to achieve a viable therapeutic window in
he general population.
ummary and Future Landscape
enomics is impacting CVD drug development today and
ffers the potential to provide significant future impact.
enomics is already providing demonstrable value for target
dentification and validation. Genetic efforts in rodent
odels and humans have provided valuable information
ith respect to CV drug targets. Progress in using genomics
s a tool for discovering biomarkers and improving outcome
rial design has been made and, over the next 10 years, the
outine application of genomics to clinical decision making
nd responder segment identification will emerge. For
enetics to fulfill its ultimate value proposition, a systems
iology approach will be necessary to differentiate causality
rom association and through pathway analysis to help
dentify druggable targets. Systems biology will significantly
mprove our ability to bring well-validated novel targets into
he clinic.
The successful application of genomics to CV drug
evelopment will require aligned and collaborative efforts of
cademia, governments, cross-functional industries, and
egulatory bodies. Future eras will be dominated by massive
dvances in technology, information handling, and compu-
ational power. Maximizing the value offered by these new
echnological capabilities will require access to patients,
ata, samples, and patient consent for genomic studies. This
nderscores the need for comprehensive biobanks, which
re repositories for biological samples (including deoxyribo-
ucleic acid) from a representative portion of a human
opulation with associated information describing the peo-
le to whom the samples belong.
Several biobanks exist and others are under development.
he United Kingdom Biobank intends to archive data and
amples on 500,000 patients (97). The Nordic countries
ave pioneered biobanking and have established several,
ncluding 1 in Iceland that began as part of the Reykjavik
eart Study utilized by deCODE Genetics to successfully
dentify several CVD genes (98). The Japanese Biobank
tarted in 2003 with the purpose of collecting deoxyribonucleic
cid, serum, and clinical information from 300,000 subjects
n Japan (99). While these represent an important first step,
fforts are needed to establish larger, information-rich bio-
anks, in which systems-based genomic approaches will help
dentify new CVD targets and biomarkers with which pro-
pectively enrolled clinical trials can be conducted in targeted
atient segments. Indeed, the ability to screen a biobank for a
esponse or safety marker in advance of recruitment will help
perationalize segmentalized medicine. The aforementioned
ioImage study (Fig. 4) represents 1 example of this type ofcreening approach. With the availability of biobanks, inhich we will be able to apply advancing genomic tools and
everage systems biology approaches to samples and data, we
ill find novel and well-validated targets to pursue new
VD therapies. If established correctly with the appropriate
onsent, these same biobanks will serve as a source for
dentifying and studying the patient segments that will
enefit the most from these novel therapies. To work, this
ndertaking will require time and the collaborative efforts of
overnments, academia, patients, patient advocacy groups,
ayers, and industry.
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